ArticleClinical and experimental immunology2001
Evidence of a role for CD200 in regulation of immune rejection of leukaemic tumour cells in C57BL/6 mice.
Article in Clinical and experimental immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 56 citations in OpenAlex.
- Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.International journal of molecular sciences · 2023Review
- The immunoregulatory protein CD200 as a potentially lucrative yet elusive target for cancer therapy.Oncotarget · 2023Review
- The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.Cancer research · 2021Article
- Impact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single CenterTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
- The Roles of Alternative Splicing in Tumor-immune Cell Interactions.Current cancer drug targets · 2020Review
- CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.Advances in experimental medicine and biology · 2020Review
- Pre-transplant CD200 and CD200R1 concentrations are associated with post-transplant events in kidney transplant recipients.Medicine · 2019Article
- CD200fc enhances anti-tumoral immune response and inhibits visceral metastasis of breast carcinoma.Oncotarget · 2018Article
- Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.Current drug targets · 2017Review
- A Critical Role for CD200R Signaling in Limiting the Growth and Metastasis of CD200+ Melanoma.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- A new insight into viral proteins as Immunomodulatory therapeutic agents: KSHV vOX2 a homolog of human CD200 as a potent anti-inflammatory protein.Iranian journal of basic medical sciences · 2016Review
- Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Oncotarget · 2015Article
- A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015Article
- Article
- Programmed cell removal: a new obstacle in the road to developing cancer.Nature reviews. Cancer · 2011Review
- CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia.Leukemia · 2011Article
- Alternative splicing of CD200 is regulated by an exonic splicing enhancer and SF2/ASF.Nucleic acids research · 2010Article
- Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy.European journal of immunology · 2010Article
- Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- mRNA expression profiling reveals a role of Helicobacter pylori vacuolating toxin in escaping host defense.World journal of gastroenterology · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased expression of the molecule CD200 in mice receiving renal allografts is associated with immunosuppression leading to increased graft survival, and altered cytokine production in lymphocytes harvested from the transplanted animals. Preferential production of IL-4, IL-10 and TGFbeta occurs on donor-specific restimulation in vitro, with decreased production of IL-2, IFNgamma and TNFalpha. These effects are enhanced by simultaneous infusion of CD200 immunoadhesin (CD200Fc) and donor CD200 receptor (CD200r) bearing macrophages to transplanted mice. C57BL/6 mice do not normally resist growth of EL4 or C1498 leukaemia tumour cells. Following transplantation of cyclophosphamide-treated C57BL/6 with T-depleted C3H bone marrow cells, or for the EL4 tumour, immunization of C57BL/6 mice with tumour cells transfected with a vector encoding the co-stimulatory molecule CD80 (EL4-CD80), mice resist growth of tumour challenge. Immunization of C57BL/6 mice with EL4 cells overexpressing CD86 (EL4-CD86) is ineffective. Protection from tumour growth in either model is suppressed by infusion of CD200Fc, an effect enhanced by co-infusion of CD200r+ macrophages. CD200Fc acts on both CD4+ and CD8+ cells to produce this suppression. These data are consistent with the hypothesis that immunosuppression following CD200-CD200r interaction can regulate a functionally important tumour growth inhibition response in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.